Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …

Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate
the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting …

The incidence of melanoma is increasing worldwide and despite early detection and
intervention, the number of patients dying from metastatic disease continues to rise. The …

Metastatic melanoma is notorious for its immune evasion and resistance to conventional
chemotherapy. The recent success of ipilimumab, a human monoclonal antibody against …

Melanomas are tumors originating from melanocytes and tend to show early metastasis
secondary to the loss of cellular adhesion in the primary tumor, resulting in high mortality …

Immunotherapy is an important modality in the therapy of patients with malignant melanoma.
As our knowledge about this disease continues to expand, so does the immunotherapeutic …

Historically, the median overall survival for patients with stage IV melanoma was less than 1
year and the 5-year survival rate was∼ 10%. Recent advances in therapy have raised 5 …

Immunotherapy is associated with durable clinical benefit in patients with melanoma. The
goal of this article is to provide evidence‑based consensus recommendations for the use of …

Background Cancer immunotherapy has been firmly established as a standard of care for
patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials …

Melanoma is one of the most immunologic malignancies based on its higher prevalence in
immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary …